Brokerages Set Affimed (NASDAQ:AFMD) Target Price at $45.00

Shares of Affimed (NASDAQ:AFMD) have been given an average rating of “Buy” by the five brokerages that are currently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have covered the stock in the last year is $45.00.

A number of analysts have recently issued reports on AFMD shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Monday. Finally, Wells Fargo & Company lowered their price target on Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st.

Institutional Investors Weigh In On Affimed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP purchased a new stake in Affimed in the fourth quarter valued at $341,000. BNP Paribas Financial Markets raised its position in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the period. EWA LLC purchased a new stake in Affimed in the fourth quarter valued at $89,000. Finally, abrdn plc purchased a new stake in Affimed in the fourth quarter valued at $130,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $6.68 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.25 and a quick ratio of 3.23. The business’s 50 day moving average price is $5.34 and its 200-day moving average price is $5.28. The firm has a market capitalization of $101.74 million, a PE ratio of -0.80 and a beta of 2.04. Affimed has a 1 year low of $2.23 and a 1 year high of $8.82.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.